Graphite Bio has agreed to merge into LENZ Therapeutics, creating a combined company focused on advancing LENZ’s lead pipeline candidates, designed to address presbyopia—nearly a year after Graphite ...

The first patient treated with Graphite Bio's gene-editing program suffered a serious side effect. The biotech halted the trial while it investigates the case, which may impact other CRISPR companies.

One dose, one cure. Countless researchers with this dream have worked for decades toward developing life-saving medicines for genetic diseases. That’s gene therapy’s goal: to fix DNA errors and see a ...